Substantial Triglyceride Reduction With Plozasiran

In patients with severe hypertriglyceridemia who are at risk for acute pancreatitis, the drug brought about triglyceride reductions of more than 50% in the phase 2 SHASTA-2 study.

Related Keywords

Georgia ,United States ,Canada ,Montreal ,Quebec ,North Carolina ,Atlanta ,Neha Pagidipati ,Daniel Gaudet ,University Of Montreal ,American College Of Cardiology Annual Scientific Session ,Duke Clinical Research Institute ,American College ,Annual Scientific Session ,Lipids ,Ipid Management ,Triglycerides ,Cv Risk ,Cardiovascular Risk ,V Risk Factors ,Cardiovascular Risk Factors ,Cardiovascular Risk Management ,Abdominal Infection ,Pancreatitis ,Hypertriglyceridemia Hypertriglyceridaemia ,Acute Pancreatitis ,Atherosclerotic Heart Disease ,Therosclerotic Cardiovascular Disease ,Oronary Heart Disease ,Schemic Heart Disease ,Coronary Artery Disease ,